- Home
- FFA vs NGNE Comparison
FFA vs NGNE Comparison
Compare FFA & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFA | NGNE |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.9M | 498.2M |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FFA | NGNE |
|---|---|---|
| Price | $22.77 | $39.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $63.57 |
| AVG Volume (30 Days) | 28.5K | ★ 305.2K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.50 | $15.93 |
| 52 Week High | $23.24 | $43.66 |
Technical Indicators
Market Signals| Indicator | FFA | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 63.72 |
| Support Level | $21.65 | $18.24 |
| Resistance Level | $23.24 | N/A |
| Average True Range (ATR) | 0.22 | 3.11 |
| MACD | 0.06 | 0.51 |
| Stochastic Oscillator | 100.00 | 70.00 |
Price Performance
Historical ComparisonAbout FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.